Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms ...

Minnesota clinics are starting to receive free or low-cost insulin from Eli Lilly and Sanofi. This comes after the Minnesota ...

BPGbio, a pioneering biology-first, AI-powered, clinical-stage biopharma specializing in mitochondrial biology and protein homeostasis, and Joslin Diabetes Center, the world's leading diabetes care ...

The Court of Appeals (CA) has denied the motion for reconsideration filed by French drugmaker Sanofi Pasteur Inc. over the ...

Due to the plethora of investment options such as equities, bonds, and mutual funds that are available today, picking the ...

The government’s antitrust watchdog on Friday sued three massive health conglomerates, accusing their drug middlemen of forcing insulin prices to skyrocket since 2012. The Federal Trade Commission ...

Sanofi (SNY) has won bindings bids for its consumer health division from private equity firms CD&R and PAI Partners. Read ...

Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion ...

Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi invested in a struggling biotech and shares of two Duchenne drug developers ...

In a landmark move, the FTC filed a lawsuit targeting the “Big Three” PBMs: CVS Health’s Caremark Rx, Cigna’s Express Scripts (ESI), and UnitedHealth Group’s OptumRx. The suit also includes their ...

After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.